These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 11249591)
41. Emerging mechanisms of fluoroquinolone resistance. Hooper DC Emerg Infect Dis; 2001; 7(2):337-41. PubMed ID: 11294736 [TBL] [Abstract][Full Text] [Related]
42. Discovery of Azaindole Ureas as a Novel Class of Bacterial Gyrase B Inhibitors. Zhang J; Yang Q; Cross JB; Romero JA; Poutsiaka KM; Epie F; Bevan D; Wang B; Zhang Y; Chavan A; Zhang X; Moy T; Daniel A; Nguyen K; Chamberlain B; Carter N; Shotwell J; Silverman J; Metcalf CA; Ryan D; Lippa B; Dolle RE J Med Chem; 2015 Nov; 58(21):8503-12. PubMed ID: 26460684 [TBL] [Abstract][Full Text] [Related]
43. Novel antimicrobial agents against multi-drug-resistant gram-positive bacteria: an overview. Giannakaki V; Miyakis S Recent Pat Antiinfect Drug Discov; 2012 Dec; 7(3):182-8. PubMed ID: 23016758 [TBL] [Abstract][Full Text] [Related]
44. Synergy and antagonism of fluoroquinolones with other classes of antimicrobial agents. Neu HC Drugs; 1993; 45 Suppl 3():54-8. PubMed ID: 7689452 [TBL] [Abstract][Full Text] [Related]
45. In Vitro and in Vivo Evaluation of Membrane-Active Flavone Amphiphiles: Semisynthetic Kaempferol-Derived Antimicrobials against Drug-Resistant Gram-Positive Bacteria. Lin S; Li H; Tao Y; Liu J; Yuan W; Chen Y; Liu Y; Liu S J Med Chem; 2020 Jun; 63(11):5797-5815. PubMed ID: 32400157 [TBL] [Abstract][Full Text] [Related]
47. Impermeability to quinolones in gram-positive and gram-negative bacteria. Bryan LE; Bedard J Eur J Clin Microbiol Infect Dis; 1991 Apr; 10(4):232-9. PubMed ID: 1864283 [TBL] [Abstract][Full Text] [Related]
48. Novel tetrahydropyran-based bacterial topoisomerase inhibitors with potent anti-gram positive activity and improved safety profile. Surivet JP; Zumbrunn C; Rueedi G; Bur D; Bruyère T; Locher H; Ritz D; Seiler P; Kohl C; Ertel EA; Hess P; Gauvin JC; Mirre A; Kaegi V; Dos Santos M; Kraemer S; Gaertner M; Delers J; Enderlin-Paput M; Weiss M; Sube R; Hadana H; Keck W; Hubschwerlen C J Med Chem; 2015 Jan; 58(2):927-42. PubMed ID: 25494934 [TBL] [Abstract][Full Text] [Related]
49. Efflux-mediated resistance to fluoroquinolones in gram-positive bacteria and the mycobacteria. Poole K Antimicrob Agents Chemother; 2000 Oct; 44(10):2595-9. PubMed ID: 10991829 [No Abstract] [Full Text] [Related]
50. Impact of the fluoroquinolones on gastrointestinal flora. Korten V; Murray BE Drugs; 1993; 45 Suppl 3():125-33. PubMed ID: 7689443 [TBL] [Abstract][Full Text] [Related]
54. [New fluoroquinolones and treatment of acute sinusitis]. Gehanno P; Trémolières F Presse Med; 1999 Sep; 28(25):1365. PubMed ID: 10506868 [No Abstract] [Full Text] [Related]
55. Premafloxacin: a projected veterinary use fluoro-quinolone with significant activity against multi-resistant gram-positive human pathogens. Zerva L; Marshall SA; Jones RN J Antimicrob Chemother; 1996 Oct; 38(4):742-4. PubMed ID: 8937972 [No Abstract] [Full Text] [Related]
56. Biological activity and synthetic metodologies for the preparation of fluoroquinolones, a class of potent antibacterial agents. Da Silva AD; De Almeida MV; De Souza MV; Couri MR Curr Med Chem; 2003 Jan; 10(1):21-39. PubMed ID: 12570719 [TBL] [Abstract][Full Text] [Related]
57. The fluoroquinolones: how long will their utility last? Bakken JS Scand J Infect Dis; 2004; 36(2):85-92. PubMed ID: 15061660 [TBL] [Abstract][Full Text] [Related]